Back to Search Start Over

Wound recovery efficacy of retinol based-micellar formulations in an organotypic skin wound model.

Authors :
Oluwole DO
Diaz-Delgado J
Buchanan W
La Ragione RM
Chen T
Liu LX
Source :
International journal of pharmaceutics [Int J Pharm] 2024 Mar 25; Vol. 653, pp. 123875. Date of Electronic Publication: 2024 Feb 03.
Publication Year :
2024

Abstract

Impairment of the skin's structural integrity initially results in acute wounds which can become chronic if timely wound closure is not achieved. Chronic wounds (CWs) affect more than 1% of the global population with increasing cases of this condition due to the ageing population. Current wound management relies on debridement, hyperbaric oxygen, antibiotics, and wound dressings, which lack early intervention and specificity. Herein, antibiotics-free retinol-based micellar formulations (RMF) were made and their wound healing efficacy were investigated in vitro. Five different formulations with retinol contents of 0.3% and 1% against a placebo were topically applied to an organotypic full-thickness skin wound model (FT-SWM, MatTek®) with a 3 mm punch wound, and maintained in an incubator for 6 days. The histological analysis of the FT-SWM was conducted at depths of 60 µm and 80 µm. It was found that all the micellar retinol formulations accelerated wound bed contraction, with 0.3% RMF demonstrating the highest efficacy. At the depths of 60 µm and 80 µm, the 0.3% RMF exhibited inner wound diameter contraction of 58% and 77%, respectively, in comparison to the placebo showing 15% and 8%. The RMF significantly accelerated wound healing and can thus be a potential early intervention for speedy wound recovery. It should be pointed out that these results were obtained based on a small sample size and a large sample size will be explored to further validate the results.<br />Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Will Buchanan is a director at Phytoceutical Limited. Some of the developments described in this paper are covered by Phytoceutical Ltd IP (Br. Pat. GB2550346 and Eur. Pat. App. 17724421.7). Phytoceutical Limited or the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.<br /> (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-3476
Volume :
653
Database :
MEDLINE
Journal :
International journal of pharmaceutics
Publication Type :
Academic Journal
Accession number :
38316316
Full Text :
https://doi.org/10.1016/j.ijpharm.2024.123875